Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 125 participants.

Also called NCT03604198

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03604198
  • EU CT 2024-514079-17-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Austria, Canada, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03604198. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-07 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Condition
Cushing Syndrome
Intervention (Drug)
relacorilant
Lead sponsor
Corcept Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03604198
Content hash
c6ce9352e18b535516f7cd5dc1d31d58113784a2700d1622b36eb9a1ebe94872